How The U.S. Can Beat China In Biotech

China’s emergence as a biopharma powerhouse has become a hot topic in the industry.

Observers point to growing numbers of biotech startups, a surge in drug approvals, and major licensing deals flowing westward from China. This prompts worries that America could lose its long-held lead in biopharma innovation.

Before panicking, though, it’s important to step back and examine the root cause of China’s new prominence. There’s no magic to China’s biopharma boom; rather, it is the predictable result of its well-known ability to take commoditized business activities and scale them up.

The path forward for continuing U.S. leadership becomes much clearer with the underlying drivers properly understood.